DUBLIN, Dec. 14, 2020 /PRNewsCentre/ — The "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast – 2030" report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.
The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
Comprehensive insight has been provided into the Acute Respiratory Distress Syndrome (ARDS) epidemiology and treatment.
Additionally, an all-inclusive account of both the current and emerging therapies for Acute Respiratory Distress Syndrome (ARDS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of Acute Respiratory Distress Syndrome (ARDS) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.
The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Scope of the Report
Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is anticipated to rise in the forecasted period (2017-2030).
The market for ARDS in the 7MM is projected to rise during the study period (2017-2030).
Dynamic research and developmental activity with 60+ companies in the pipeline at different stages.
In the coming years, Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for Acute Respiratory Distress Syndrome (ARDS). Launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome (ARDS) market.
The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Key Topics Covered:
Ache Laboratorios Farmaceuticos
Ampio Pharmaceuticals Inc.
Apeptico Forschung und Entwicklung GmbH
Aqualung Therapeutics Corp.
Bioaegis Therapeutics Inc.
Biohaven Pharmaceutical Holding Co. Ltd.
Caladrius Biosciences Inc.
Celularity Inc.; Sorrento Therapeutics Inc.; Lung Biotechnology PBC, a subsidiary of United Therapeutics Corp.
Diffusion Pharmaceuticals Inc.; University of Virginia
Eli Lilly and Company
Hospital to Academy of Military Medical Sciences/Ivy Institute of Stem Cells Co. Ltd
Kinevant Sciences GmbH/Roivant Sciences
Laboratoire francais de Fractionnement et de Biotechnologies
Lamellar Biomedical Ltd.
Lattice Biologics Ltd.
Leading Biosciences Inc.
Mallinckrodt /Novoteris LLC
Mannkind Corp.; Immix Biopharma Inc.
Predictive Biotech, of Salt Lake City, a subsidiary of Predictive Technology Group
Roche Pharma AG
Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
1 Key Insights
2 Executive Summary
3 Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance
4 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview
5 Case Reports
6 Epidemiology and Patient Population
7 7MM Epidemiology Analysis
8 United States Epidemiology
9 EU5 Epidemiology
10 Japan Epidemiology
11 Treatment Algorithm, Current Treatment, and Medical Practices
12 Proposed Guidelines for ARDS
13 Unmet Needs
14 Off-Label Therapies for ARDS
15 Emerging Therapies
16 Unknown Status
17 COVID-19 associated with ARDS: Emerging Drugs
18 Discontinued Products
19 Acute Respiratory Distress Syndrome (ARDS): 7MM Market Analysis
20 Attribute Analysis
21 Key Emerging Therapies: Market Forecast Assumptions
22 United States: Market Outlook
23 EU-5 Countries: Market Outlook
24 Japan Market Outlook
25 Access and Reimbursement
26 Market Drivers
27 Market Barriers
28 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/cwxz59
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE: Research and Markets